Harvard Bioscience, Inc. · NASDAQ:HBIO
Harvard Bioscience — Sidoti Virtual Conference (September 2024)
17 slides from Harvard Bioscience's conference presentation, Sep 18, 2024
Slide 1: HBIO Investor Overview
Enabling discovery, safety and production of tomorrow’s therapeutics NASDAQ: HBIO HBIO Investor Overview Sidoti Virtual Conference September 18, 2024 Jim Green, Chairman, President & CEO Jennifer Cote, CFO & Treasurer
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified
Slide 3: Trusted provider of advanced life science tools to leading academic research institutions
Trusted provider of advanced life science tools to leading academic research institutions, contract research organizations, pharmaceutical and bio-tech companies COMPANY PROFILE ▪ NASDAQ: HBIO ▪ Global sales footprint, 3 core manufacturing facilities ▪ Approx. 383 employees, 33 PhD, 54 Masters, 77 B
Slide 4: Harvard Bioscience Investment Thesis
Harvard Bioscience Investment Thesis Long standing relationships with blue- Essential natural growth end markets DIVERSIFIED CUSTOMER / chip customers REVENUE MODEL Systems & Software Direct sales force complemented by High touch sales approach with elite distributors for global reach applications &
Slide 5: Sales and Earnings Trends
Sales and Earnings Trends REVENUES ADJUSTED EBITDA & EBITDA MARGIN* Portfolio Optimization **** $5.5M FY22/ $0.5M FY23 $113M $112M 8/8/24 Revenue Outlook FY24 $97M-$102M** 8/8/24 Adj EBITDA Margin Outlook H1 H1 H1 high single digits** $15M $11M 13% $11M 10% 10% H2 H2 H2*** * Non-GAAP measure; see re
Slide 6: Today’s Global Footprint
Today’s Global Footprint CELLULAR & PRE- MOLECULAR CLINICAL Stuttgart, Germany SYSTEMS CELLULAR & Minneapolis MOLECULAR AND HBIO HEADQUARTERS Boston Core Operating Site Sales Office / Small Centers of Excellence 1-1-19 8-31-24 Employees* 547 383 Product Lines 18 10 *Headcount is approximate Sites 14
Slide 7: Essential Technologies Serving Well-funded, High-growth Secular Markets with Demographic Tailwinds
Essential Technologies Serving Well-funded, High-growth Secular Markets with Demographic Tailwinds DRIVERS Rising incidence of disease – Increased demand for research tools, cardiac, cancer, respiratory, Increased funding for research and devices and systems that improve diabetes, obesity, Alzheimer
Slide 8: Blue Chip Customer Base
Blue Chip Customer Base CONTRACT ACADEMIC BIOTECH, RESEARCH RESEARCH PHARMACEUTICAL ORGANIZATIONS • Scientific Research labs primarily • Pre-clinical studies to determine • Perform early discovery and then government & grant funded safety and efficacy of new transition from discovery through pre- ph
Slide 9: Drug Development Cycle: Today
Drug Development Cycle: Today Regulatory Report Research & Discovery Pre-Clinical Safety & Toxicology Bio-Production Low Yield COMPOUND CELLULAR SMALL MODEL LARGE / NHP CLINICAL CREATION TESTINGS LARGE SAFETY MODEL SAFETY POPULATION Cellular Platforms Implanted Telemetry (Electrophysiology) Micro El
Slide 10: Reducing Cycle Time: Introducing the MeshMEA Organoid Platform
Reducing Cycle Time: Introducing the MeshMEA Organoid Platform Regulatory Report Research & Discovery Pre-Clinical Safety & Toxicology Bio-Production Low Yield COMPOUND CELLULAR ORGANOIDS SMALL MODEL LARGE / NHP CLINICAL CREATION TESTINGS LARGE SAFETY MODEL SAFETY POPULATION Cellular Platforms First
Slide 11: New Product Introductions: Focused on Commercialization
New Product Introductions: Focused on Commercialization EXPAND TO HIGH GROWTH: EXPAND TO HIGH GROWTH: IN- STRENGTHEN THE BASE: DELIVER > MARKET GROWTH BIO-PRODUCTION VITRO ORGANOID APPS PRECLINICAL CMT CMT- ORGANOIDS • Ponemah Enterprise Data Acquisition/Analysis GLP • Established BTX brand for • In
Slide 12: 2024 New Product Introductions: Supports Long Term Growth Targets
2024 New Product Introductions: Supports Long Term Growth Targets Growth Category Product Line Application Customers Commercial Status Key Trade Show Product Focus • Federation of European Neuroscience Societies • CROs • Q3: Soho Production • SoHo Shared • Safety Shipments Housing Telemetry Pharmaco
Slide 13: Investment Thesis: Deliver Strong, Profitable, Long-Term Growth
Investment Thesis: Deliver Strong, Profitable, Long-Term Growth NEW PRODUCT INTRODUCTIONS FOCUSED ON TOP-LINE GROWTH & RECURRING REVENUES LARGE, LOYAL CUSTOMER BASE IN DRUG RESEARCH & DISCOVERY, SAFETY & REGULATORY, AND BIO-PRODUCTION MARKETS FOCUSED ON LONG TERM DOUBLE DIGIT TOPLINE GROWTH, 60% GRO
Slide 14: Thank You
Enabling discovery, safety and production of tomorrow’s therapeutics Thank You
Slide 15: Appendix
Appendix 15
Slide 16: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands) Year Ended Year Ended 31-Dec-22 31-Dec-23 GAAP net loss $ (9,516) $ (3,415) Stock-based compensation 4,411 5,000 Acquired asset amortization and impairment 6,236 5,561 Settlement, restructuring, & other 5,603 253 Unrealized loss
Slide 17: Expand to Bio-Production: BTX Electroporation as a Bridge to Bio-Production
Expand to Bio-Production: BTX Electroporation as a Bridge to Bio-Production HBIO IS A PIONEER IN ELECTROPORATION AND ELECTROFUSION DRIVING NOVEL DISCOVERIES IN DRUG CREATION Bio30+ AAA system AgilePulseTM MAX Consumable: Flatpack ECM 2001+ Reaction Chamber Bio-Production Applications and Configurati
Harvard Bioscience — Sidoti Virtual Conference (September 2024) on 6ix